- Conjugation of 2’-O-hexadecyl (C16) to siRNA Enables Therapeutic Silencing of Target Genes Outside the Liver with Infrequent Dosing in Rodents and Non-Human Primates - - In a Mouse Model of ...
Preclinical data shows use of megalin receptors for intracellular delivery of a ligand-siRNA conjugate to silence production of target mRNA in the kidney Megalin-binding genetic medicines are ...
PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues ...
Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...
Discover how a newly developed platform technology from The University of North Carolina at Chapel Hill can enhance RNAi ...
Alnylam has set out how it plans to deliver siRNA to the central nervous system and other tissues beyond the liver. Writing in Nature Biotechnology, the RNA specialist shared details of how the ...
SHANGHAI and SANTA BARBARA, Calif., Dec. 15, 2025 /PRNewswire/ -- Rona Therapeutics, a clinical-stage RNAi company, today announced the recent completion of Cohort 1 dosing in its Phase 1 ...
Researchers from Suzhou Siran Biotech Co. Ltd. presented the discovery and preclinical characterization of SA-1211, an N-acetylgalactosamine (GalNAc)-conjugated siRNA dimer targeting both hepatitis B ...
KAWASAKI, Japan, December 18, 2025--(BUSINESS WIRE)--PeptiDream Inc., a public Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587), announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results